Corxel to go public via Amanat SPAC merger, backed by $300M PIPE
What's the deal? Corxel Pharmaceuticals has agreed to merge with Amanat Acquisition CorpDealroom has a profile for this one. Try Dealroom →, a Nasdaq-listed special purpose acquisition company, to form a publicly traded obesity-focused biopharmaceutical business. Corxel will become a wholly owned subsidiary of the combined company, which will take a new name and ticker before closing.
What's the money? The deal pairs roughly $75 million in Amanat's trust account with a concurrent, oversubscribed private investment in public equity (PIPE) of about $300 million. Together, that is expected to generate approximately $377 million in gross proceeds, assuming no redemptions by Amanat shareholders.
Who's backing it? PIPE participants include RTW InvestmentsDealroom has a profile for this one. Try Dealroom →, New Enterprise Associates, SR OneDealroom has a profile for this one. Try Dealroom →, HBM Healthcare InvestmentsDealroom has a profile for this one. Try Dealroom →, InvusDealroom has a profile for this one. Try Dealroom →, RA Capital Management, and a large healthcare mutual fund, among others. RTW founded Corxel in 2019.
What's the endgame? Corxel is building an oral obesity franchise led by CX11, a once-daily oral small-molecule GLP-1 receptor agonist, and CX12, a preclinical oral amylin receptor agonist. CX11 showed clinically meaningful weight loss and a generally favourable tolerability profile across Phase 2 studies in the US.
Why now? After an End-of-Phase 2 meeting, Corxel has aligned with the US Food and Drug Administration on CX11's regulatory path and Phase 3 trial design. Proceeds are expected to fund the company through 2029, including a planned global Phase 3 obesity program.
What could go wrong? The merger is slated to close in the first half of 2027 and depends on shareholder approval and redemption levels. PIPE investors can also reduce their commitments by buying Amanat shares in the open market, which could cut the final cash raised.
The signal: The SPAC route gives Corxel a path to public markets as investor appetite for obesity drugs climbs. But the bar has risen: Novo Nordisk and Eli Lilly already sell oral obesity treatments, so Corxel's clinical-stage assets and funding runway — not its obesity focus alone — will decide whether it stands out.
Read more: pr.lakeoconeebreeze.net
Image credit: Generated with Gemini
